Treatment of cancer with cryochemotherapy

Cryosurgery employs freezing to destroy solid tumours. However, frozen cells can survive and cause cancer recurrence. Bleomycin, an anticancer drug with a huge intrinsic cytotoxicity is normally not very effective because it is nonpermeant. We report that freezing facilitates bleomycin penetration i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mir, L M, Rubinsky, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746597/
https://www.ncbi.nlm.nih.gov/pubmed/12085219
http://dx.doi.org/10.1038/sj.bjc.6600306
_version_ 1782172054576955392
author Mir, L M
Rubinsky, B
author_facet Mir, L M
Rubinsky, B
author_sort Mir, L M
collection PubMed
description Cryosurgery employs freezing to destroy solid tumours. However, frozen cells can survive and cause cancer recurrence. Bleomycin, an anticancer drug with a huge intrinsic cytotoxicity is normally not very effective because it is nonpermeant. We report that freezing facilitates bleomycin penetration into cells making it toxic to cryosurgery surviving cells at concentrations that are non-toxic systemically. British Journal of Cancer (2002) 86, 1658–1660. DOI: 10.1038/sj/bjc/6600306 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2746597
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27465972009-09-18 Treatment of cancer with cryochemotherapy Mir, L M Rubinsky, B Br J Cancer Experimental Therapeutics Cryosurgery employs freezing to destroy solid tumours. However, frozen cells can survive and cause cancer recurrence. Bleomycin, an anticancer drug with a huge intrinsic cytotoxicity is normally not very effective because it is nonpermeant. We report that freezing facilitates bleomycin penetration into cells making it toxic to cryosurgery surviving cells at concentrations that are non-toxic systemically. British Journal of Cancer (2002) 86, 1658–1660. DOI: 10.1038/sj/bjc/6600306 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-05-20 2002-05-03 /pmc/articles/PMC2746597/ /pubmed/12085219 http://dx.doi.org/10.1038/sj.bjc.6600306 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Experimental Therapeutics
Mir, L M
Rubinsky, B
Treatment of cancer with cryochemotherapy
title Treatment of cancer with cryochemotherapy
title_full Treatment of cancer with cryochemotherapy
title_fullStr Treatment of cancer with cryochemotherapy
title_full_unstemmed Treatment of cancer with cryochemotherapy
title_short Treatment of cancer with cryochemotherapy
title_sort treatment of cancer with cryochemotherapy
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746597/
https://www.ncbi.nlm.nih.gov/pubmed/12085219
http://dx.doi.org/10.1038/sj.bjc.6600306
work_keys_str_mv AT mirlm treatmentofcancerwithcryochemotherapy
AT rubinskyb treatmentofcancerwithcryochemotherapy

Ejemplares similares